SCHEMBL9505269

SCHEMBL9505269

Cc1ccn(C)c(=O)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
CYP2C9 P11712 2/20 0.52
KDM6A O15550 1/20 0.52
KDM4A O75164 1/20 0.52
CYP2C19 P33261 1/20 0.52
KDM5C P41229 1/20 0.52
KDM2B Q8NHM5 1/20 0.52
DOHH Q9BU89 1/20 0.52
KDM2A Q9Y2K7 1/20 0.52
ALDH1A1 P00352 4/20 0.39
BRD4 O60885 2/20 0.38
TAF1 P21675 1/20 0.38
BRPF1 P55201 1/20 0.38
CREBBP Q92793 1/20 0.38
CECR2 Q9BXF3 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
LIPG Q9Y5X9 5/20 0.36
ALOX15 P16050 1/20 0.36
CRBN Q96SW2 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17621624 0.76 BRD4 (0.41) KDM4ECYP2C9KDM6AKDM4ACYP2C19
Hydrochloric Acid SCHEMBL30032118 0.74 BRD4 (0.39) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL27302249 0.74 KDM4E (0.39) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL15739595 0.74 ALDH1A1 (0.36) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL15613418 0.74 GABRA1 (0.46) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL24112194 0.73 ATAD2 (0.40) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL21575044 0.73 BRD4 (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL12033675 0.73 KDM4E (0.47) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL21921079 0.73 BRD4 (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19
SCHEMBL20516739 0.73 BRD4 (0.38) KDM4ECYP2C9KDM6AKDM4ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170340759-A1 RADIO-PHARMACEUTICAL COMPLEXES BAYER AS (NO) 2017-11-30 US disclosed
US-20170183365-A1 MACROCYCLES LUMIPHORE, INC. 2017-06-29 US disclosed
US-9439984-B2 Macrocycles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-09-13 US disclosed
US-20160221971-A1 DI-MACROCYCLES LUMIPHORE, INC. (US) 2016-08-04 US disclosed
US-20150157746-A1 MACROCYCLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-06-11 US disclosed
CN-100575345-C 2 type Cannabined receptors are had in conjunction with active Pyridione derivatives SHIONOGI & CO 2009-12-30 CN disclosed
CN-1492856-A Pyridone derivative having affinity for cannabinoid 2-type receptor ��Ұ����ҩ��ʽ���� 2004-04-28 CN disclosed
EP-0297397-B1 PREPARATION OF DIAZO AND AZO COMPOUNDS BAYER AG (DE) 1993-08-04 EP disclosed
US-4942225-A Preparation of diazo and azo compounds using azidoformamidium salts BAYER AKTIENGESELLSCHAFT (DE) 1990-07-17 US disclosed
EP-0093306-B1 METHODS FOR THE PREPARATION OF AZO COMPOUNDS, AND AZO COMPOUNDS BAYER AG (DE) 1986-09-24 EP disclosed
EP-0093306-A1 Methods for the preparation of azo compounds, and azo compounds BAYER AG (DE) 1983-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221971-A1 DI-MACROCYCLES DLD, NDC1, MCL1 KDM4E 4621/4885CYP2C9 1653/4885KDM6A 4857/4885
US-20170183365-A1 MACROCYCLES HCCS, ABCB7, AURKAIP1 KDM4E 4482/4885CYP2C9 1417/4885KDM6A 4757/4885
US-20150157746-A1 MACROCYCLES SLC39A14, SLC39A3, SLC40A1 KDM4E 2971/4885CYP2C9 2910/4885KDM6A 3608/4885
US-20170340759-A1 RADIO-PHARMACEUTICAL COMPLEXES PTMS, THOP1, PHPT1 KDM4E 4022/4885CYP2C9 3756/4885KDM6A 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.